WO2009001095A3 - Novel schizophrenia associated genes - Google Patents

Novel schizophrenia associated genes Download PDF

Info

Publication number
WO2009001095A3
WO2009001095A3 PCT/GB2008/002204 GB2008002204W WO2009001095A3 WO 2009001095 A3 WO2009001095 A3 WO 2009001095A3 GB 2008002204 W GB2008002204 W GB 2008002204W WO 2009001095 A3 WO2009001095 A3 WO 2009001095A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
associated genes
schizophrenia
related diseases
schizophrenia associated
Prior art date
Application number
PCT/GB2008/002204
Other languages
French (fr)
Other versions
WO2009001095A2 (en
Inventor
Brian Morris
Judith Pratt
Catherine Winchester
Hiromitsu Oozeki
Original Assignee
Mitsubishi Tanable Pharma Corp
Brian Morris
Judith Pratt
Catherine Winchester
Hiromitsu Oozeki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanable Pharma Corp, Brian Morris, Judith Pratt, Catherine Winchester, Hiromitsu Oozeki filed Critical Mitsubishi Tanable Pharma Corp
Publication of WO2009001095A2 publication Critical patent/WO2009001095A2/en
Publication of WO2009001095A3 publication Critical patent/WO2009001095A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to the identification of genes involved and/or associated with schizophrenia and related diseases, as well as particular identified genes and their potential use in therapy/diagnosis of schizophrenia and related diseases. The genes are all linked to a MAP-kinase signalling chain and are PPMlE; PPMlF,- MAP2K7; MAPK9; RICS/GRIT; PTK2B/PYK2; Gab1; Gab2; Nckl; NckAPI; CrkL; PAKI; CatnKK; CAMK4; MAP4K4; TNIK; MAP3K7; and MAPK8ip1.
PCT/GB2008/002204 2007-06-28 2008-06-26 Novel schizophrenia associated genes WO2009001095A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0712524.8A GB0712524D0 (en) 2007-06-28 2007-06-28 Novel schizophrenia associated genes
GB0712524.8 2007-06-28

Publications (2)

Publication Number Publication Date
WO2009001095A2 WO2009001095A2 (en) 2008-12-31
WO2009001095A3 true WO2009001095A3 (en) 2009-03-26

Family

ID=38420842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002204 WO2009001095A2 (en) 2007-06-28 2008-06-26 Novel schizophrenia associated genes

Country Status (2)

Country Link
GB (1) GB0712524D0 (en)
WO (1) WO2009001095A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010029171A (en) * 2008-06-25 2010-02-12 Srl Inc Diagnostic method for integration dysfunction syndrome
ES2562684B1 (en) * 2014-08-04 2017-02-06 Consejo Superior De Investigaciones Científicas (Csic) ANTIPSYCHOTIC TREATMENT MONITORING METHOD

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075440A2 (en) * 2000-03-31 2001-10-11 Mitsubishi Pharma Corporation Schizophrenia related genes
EP1420068A1 (en) * 2001-07-27 2004-05-19 Japan as represented by President of Niigata University Method of analyzing nucleic acid specifying gene showing change in expression dose in schizophrenia
WO2005123955A2 (en) * 2004-06-09 2005-12-29 Children's Medical Center Corporation Methods and compositions for modifying gene regulation and dna damage in ageing
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006105516A2 (en) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating neuropsychiatric disorders
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075440A2 (en) * 2000-03-31 2001-10-11 Mitsubishi Pharma Corporation Schizophrenia related genes
EP1420068A1 (en) * 2001-07-27 2004-05-19 Japan as represented by President of Niigata University Method of analyzing nucleic acid specifying gene showing change in expression dose in schizophrenia
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005123955A2 (en) * 2004-06-09 2005-12-29 Children's Medical Center Corporation Methods and compositions for modifying gene regulation and dna damage in ageing
WO2006105516A2 (en) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating neuropsychiatric disorders
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIOSSEVA S V: "Mitogen-activated protein kinase signaling abnormalities in the cerebellum in major psychiatric disorders.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 447.7 URL - http://sf, XP009108116 *

Also Published As

Publication number Publication date
WO2009001095A2 (en) 2008-12-31
GB0712524D0 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
ATE447564T1 (en) INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF TRANS-5-CHLORINE-2-METHYL-2,3,3A,12B-TETRAHYDRO-1H-DIBENZÄ, 3:6,7ÜOXEPINOÄ4,5-CUPYRROL
DE602005014621D1 (en) 3-A4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YLÜ-N-ARYLBENZAMIDES AS INHIBITORS OF CYTOKIN PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
MY142988A (en) Novel aminobenzophenone compounds
DE602006014352D1 (en) Innerliner and tire rubber composition containing the same
IT1395519B1 (en) COMPOSITE PIECE, AS WELL AS THE USE OF THE COMPOSITE PIECE
PL1987357T3 (en) Polypeptides recognized by anti-trichinella antibodies, and uses thereof
BRPI0910383A2 (en) polyurethane and / or ammonium polycarboanth compounds
ATE475651T1 (en) ARYL-SUBSTITUTED HETEROCYCLES AND THEIR USE
WO2009001095A3 (en) Novel schizophrenia associated genes
WO2009040727A3 (en) Method of differentially diagnosing by spect different types of dementia
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
ATE496047T1 (en) PHENYLENE-BIS-OXAZOLIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS
CL2008003232A1 (en) Benzenesulfonanilide derived compounds; pharmaceutical composition comprising them; and use in the treatment of diseases of the central nervous system, cognitive dysfunctions, schizophrenia, addictive diseases, Alzheimer's disease or obesity.
ATE553088T1 (en) SUBSTITUTED QUINOLONES II
FR2883160B1 (en) MASK, IN PARTICULAR FOR THE PRACTICE OF SLIDING SPORTS
ITMO20070046A1 (en) "APPARATUS FOR THE DRIING OF MATERIALS, PARTICULARLY ZEOLITIAN OR SIMILAR"
DE502006008280D1 (en) IMINO-OXAZOLIDINE AND ITS USE AS ANTICOAGULANTS
TH93308B (en) Watch face frame
ES1056854Y (en) PICADOR / DESMENUZADOR, TO GRIND CANNABIS OR SIMILAR.
RU2007149620A (en) RAW MATERIALS FOR GOLD EXTRACTION
TH101542S (en) "Fluorescent lamp rail"
TH87605S (en) Keychain
TH101772S (en) Water glass
TH95069A (en) Precipitated silica with special surface properties.
TH22840S1 (en) "Diaper pants"

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762506

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762506

Country of ref document: EP

Kind code of ref document: A2